retatrutide fda approval 2025 is the most significant weight-loss pharmaceutical currently in clinical development. Phase 3 TRIUMPH-4 trial results (published December 2025) showed average body weight reduction of 28.7% at 68 weeks — approaching outcomes Demand for Unapproved Weight-Loss Drug

In addition to the possibility of muscle (and bone) loss, we included several other points to consider when it comes to these drugs: Many older adults stop taking semaglutide within a year

If you get a period, weight changes and improved insulin sensitivity can affect your ovulation and fertility

Oleic acid mitigates TNF--induced oxidative stress in rat cardiomyocytes

Zero Sugar, Zero Calories Perfect for calorie-conscious users

While the ingredients show modest blood sugar benefits, type 2 diabetes management requires proper medical supervision

Some common areas that pain occurs is in the neck and parts of the hand